Fungal evolution: major ecological adaptations and evolutionary transitions

MA Naranjo‐Ortiz, T Gabaldón - Biological Reviews, 2019 - Wiley Online Library
Fungi are a highly diverse group of heterotrophic eukaryotes characterized by the absence
of phagotrophy and the presence of a chitinous cell wall. While unicellular fungi are far from …

Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target Against Trypanosoma cruzi

G Benaim, AE Paniz-Mondolfi, EM Sordillo… - Frontiers in cellular …, 2020 - frontiersin.org
There is no effective cure for Chagas disease, which is caused by infection with the
arthropod-borne parasite, Trypanosoma cruzi. In the search for new drugs to treat Chagas …

Mechanism of action of miltefosine on Leishmania donovani involves the impairment of acidocalcisome function and the activation of the sphingosine-dependent …

AK Pinto-Martinez, J Rodriguez-Durán… - Antimicrobial agents …, 2018 - Am Soc Microbiol
Leishmania donovani is the causing agent of visceral leishmaniasis, a common infection
that affects millions of people from the most underdeveloped countries. Miltefosine is the …

The current directions of searching for antiparasitic drugs

K Dziduch, D Greniuk, M Wujec - Molecules, 2022 - mdpi.com
Parasitic diseases are still a huge problem for mankind. They are becoming the main cause
of chronic diseases in the world. Migration of the population, pollution of the natural …

Estrogen Receptor Antagonists Are Anti-Cryptococcal Agents That Directly Bind EF Hand Proteins and Synergize with Fluconazole In Vivo

A Butts, K Koselny, Y Chabrier-Roselló, CP Semighini… - MBio, 2014 - Am Soc Microbiol
Cryptococcosis is an infectious disease of global significance for which new therapies are
needed. Repurposing previously developed drugs for new indications can expedite the …

A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to …

A Butts, L DiDone, K Koselny, BK Baxter… - Eukaryotic …, 2013 - Am Soc Microbiol
New, more accessible therapies for cryptococcosis represent an unmet clinical need of
global importance. We took a repurposing approach to identify previously developed drugs …

Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade

M De Rycker, J Thomas, J Riley… - PLoS neglected …, 2016 - journals.plos.org
Chagas disease is a significant health problem in Latin America and the available
treatments have significant issues in terms of toxicity and efficacy. There is thus an urgent …

Escaping deleterious immune response in their hosts: lessons from trypanosomatids

A Geiger, G Bossard, D Sereno, J Pissarra… - Frontiers in …, 2016 - frontiersin.org
The Trypanosomatidae family includes the genera Trypanosoma and Leishmania,
protozoan parasites displaying complex digenetic life cycles requiring a vertebrate host and …

Down the membrane hole: Ion channels in protozoan parasites

V Jimenez, S Mesones - PLoS pathogens, 2022 - journals.plos.org
Parasitic diseases caused by protozoans are highly prevalent around the world,
disproportionally affecting developing countries, where coinfection with other …

Drug discovery for Chagas disease: impact of different host cell lines on assay performance and hit compound selection

CH Franco, LM Alcântara, E Chatelain… - Tropical Medicine and …, 2019 - mdpi.com
Cell-based screening has become the major compound interrogation strategy in Chagas
disease drug discovery. Several different cell lines have been deployed as host cells in …